Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

MSC-Based Cell Therapy for COVID-19-Associated ARDS and Classical ARDS : Comparative Perspectives

Weiss, Daniel J. and Rolandsson Enes, Sara LU orcid (2024) In Current Stem Cell Reports 10(2). p.9-19
Abstract

Purpose of Review: Despite no general conclusions regarding the therapeutic effect of MSCs on virus-induced acute lung injury in pre-clinical studies, a significant number of clinical trials using MSC-based treatment for COVID-19-associated ARDS were initiated during the global pandemic. Here, we aimed to discuss differences and similarities in clinical trials using MSC-based treatments for classical ARDS and COVID-19-associated ARDS and to raise some future perspectives. Recent Findings: Several pre-clinical studies have demonstrated that MSC treatment may not be a good treatment option for virus infections because MSCs themselves are susceptible to the virus. However, MSCs lack expression of the angiotensin-converting enzyme 2 (ACE2)... (More)

Purpose of Review: Despite no general conclusions regarding the therapeutic effect of MSCs on virus-induced acute lung injury in pre-clinical studies, a significant number of clinical trials using MSC-based treatment for COVID-19-associated ARDS were initiated during the global pandemic. Here, we aimed to discuss differences and similarities in clinical trials using MSC-based treatments for classical ARDS and COVID-19-associated ARDS and to raise some future perspectives. Recent Findings: Several pre-clinical studies have demonstrated that MSC treatment may not be a good treatment option for virus infections because MSCs themselves are susceptible to the virus. However, MSCs lack expression of the angiotensin-converting enzyme 2 (ACE2) receptor, suggesting that MSCs are not likely to be infected by the COVID-19 virus. Interestingly, recent meta-analyses demonstrated that an improved survival rate in patients with COVID-19-associated ARDS treated with MSCs was obtained in 24 out of 26 completed clinical trials. Summary: This review provides comparative perspectives on MSC-based therapy for COVID-19-associated ARDS and classical ARDS.

(Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Acute respiratory distress syndrome, Cell therapy, COVID-19, Lung, Mesenchymal stromal cells, MSCs
in
Current Stem Cell Reports
volume
10
issue
2
pages
11 pages
publisher
Springer
external identifiers
  • scopus:85178872663
ISSN
2198-7866
DOI
10.1007/s40778-023-00231-6
language
English
LU publication?
yes
id
b9526742-1c66-4703-a463-45447fec4e2a
date added to LUP
2024-01-11 12:32:36
date last changed
2025-10-14 11:50:37
@article{b9526742-1c66-4703-a463-45447fec4e2a,
  abstract     = {{<p>Purpose of Review: Despite no general conclusions regarding the therapeutic effect of MSCs on virus-induced acute lung injury in pre-clinical studies, a significant number of clinical trials using MSC-based treatment for COVID-19-associated ARDS were initiated during the global pandemic. Here, we aimed to discuss differences and similarities in clinical trials using MSC-based treatments for classical ARDS and COVID-19-associated ARDS and to raise some future perspectives. Recent Findings: Several pre-clinical studies have demonstrated that MSC treatment may not be a good treatment option for virus infections because MSCs themselves are susceptible to the virus. However, MSCs lack expression of the angiotensin-converting enzyme 2 (ACE2) receptor, suggesting that MSCs are not likely to be infected by the COVID-19 virus. Interestingly, recent meta-analyses demonstrated that an improved survival rate in patients with COVID-19-associated ARDS treated with MSCs was obtained in 24 out of 26 completed clinical trials. Summary: This review provides comparative perspectives on MSC-based therapy for COVID-19-associated ARDS and classical ARDS.</p>}},
  author       = {{Weiss, Daniel J. and Rolandsson Enes, Sara}},
  issn         = {{2198-7866}},
  keywords     = {{Acute respiratory distress syndrome; Cell therapy; COVID-19; Lung; Mesenchymal stromal cells; MSCs}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{9--19}},
  publisher    = {{Springer}},
  series       = {{Current Stem Cell Reports}},
  title        = {{MSC-Based Cell Therapy for COVID-19-Associated ARDS and Classical ARDS : Comparative Perspectives}},
  url          = {{http://dx.doi.org/10.1007/s40778-023-00231-6}},
  doi          = {{10.1007/s40778-023-00231-6}},
  volume       = {{10}},
  year         = {{2024}},
}